These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option. Piotrowski R; Zaborska B; Baran J; Sikora-Frąc M; Kułakowski P Pol Arch Med Wewn; 2016 Jun; 126(6):430-1. PubMed ID: 27305139 [No Abstract] [Full Text] [Related]
7. Rivaroxaban for cancer-associated cardiac thrombosis. Di Nisio M; Carella C; Natoli C; Porreca E; De Tursi M Am J Med; 2015 Oct; 128(10):e43-4. PubMed ID: 26071831 [No Abstract] [Full Text] [Related]
8. Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1). Suzuki S; Yamashita T; Kasai H; Otsuka T; Sagara K Thromb Res; 2017 Feb; 150():73-75. PubMed ID: 28043042 [No Abstract] [Full Text] [Related]
9. Optimal dosing of rivaroxaban is undefined. Moore TJ BMJ; 2016 Oct; 355():i5549. PubMed ID: 27756735 [No Abstract] [Full Text] [Related]
10. Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device. Cohen D BMJ; 2015 Dec; 351():h6431. PubMed ID: 26635138 [No Abstract] [Full Text] [Related]
11. Rivaroxaban: from ROCKET-AF trial to routine practice in Spain. Escobar Cervantes C Future Cardiol; 2018 May; 14(3s):1-2. PubMed ID: 29848088 [No Abstract] [Full Text] [Related]
12. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis. Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679 [No Abstract] [Full Text] [Related]
13. Thrombosis in Fontan patient on apixaban. Pinto C; Samuel BP; Ratnasamy C; Vettukattil JJ Int J Cardiol; 2015 Mar; 182():66-7. PubMed ID: 25590960 [No Abstract] [Full Text] [Related]
14. Rivaroxaban in Chronic Hemodialysis Patients. Muster H; Alcorn H Am J Nephrol; 2016; 43(4):227-8. PubMed ID: 27100995 [No Abstract] [Full Text] [Related]
15. Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants. Gaertner S; Cordeanu EM; Mirea C; Stephan D Int J Cardiol; 2015; 186():141-2. PubMed ID: 25818758 [No Abstract] [Full Text] [Related]
16. Mechanical Prosthetic Heart Valve Thrombosis in a Patient Receiving Rivaroxaban. Carvalho Silva DM; Braga A; de Jesus I; Neves J Cardiology; 2019; 143(3-4):116-120. PubMed ID: 31473736 [TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness. Tomkowski WZ; Davidson BL Thromb Res; 2019 Aug; 180():62-63. PubMed ID: 31226663 [No Abstract] [Full Text] [Related]
18. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban. Tardy-Poncet B; Piot M; Montmartin A; Burdier A; Chalayer E; Tardy B Thromb Haemost; 2015 Aug; 114(3):652-4. PubMed ID: 26062524 [No Abstract] [Full Text] [Related]
19. Superior mesenteric artery thrombosis after abrupt discontinuation of rivaroxaban. Adams CB; Acquisto NM; Rotoli JM; LoStracco T; Shamaskin AR; Pasternack JS Am J Emerg Med; 2016 Apr; 34(4):764.e5-7. PubMed ID: 26439093 [TBL] [Abstract][Full Text] [Related]